GRFS
Grifols, S.A.
Drug Manufacturers - General
Market Cap$7.11B
5Y Perf.-55.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
GRFS vs TAK
Revenue, margins, valuation, and 5-year total return — side by side.
TAK
Takeda Pharmaceutical Company Limited
Drug Manufacturers - Specialty & Generic
Market Cap$52.82B
5Y Perf.-14.3%
GRFS vs TAK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GRFS | TAK |
|---|---|---|
| Industry | Drug Manufacturers - General | Drug Manufacturers - Specialty & Generic |
| Market Cap | $7.11B | $52.82B |
| Revenue (TTM) | $7.51B | $4.49T |
| Net Income (TTM) | $401M | $114.75B |
| Gross Margin | 38.4% | 62.1% |
| Operating Margin | 17.0% | 8.3% |
| Forward P/E | 9.6x | 0.2x |
| Total Debt | $8.74B | $4.52T |
| Cash & Equiv. | $825M | $385.11B |
GRFS vs TAK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GRFS
TAK
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Grifols, S.A. (GRFS) | 100 | 44.4 | -55.6% |
| Takeda Pharmaceutic… (TAK) | 100 | 85.7 | -14.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GRFS vs TAK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TAK leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Grifols, S.A. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
GRFS
Grifols, S.A.
The Quality Compounder
GRFS is the clearest fit if your priority is quality and momentum.
- 5.3% margin vs TAK's 2.6%
- +18.9% vs TAK's +14.3%
- 2.0% ROA vs TAK's 0.7%, ROIC 5.4% vs 2.3%
Best for: quality and momentum
TAK
Takeda Pharmaceutical Company Limited
The Income Pick
TAK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 2 yrs, beta 0.33, yield 3.6%
- Rev growth 7.5%, EPS growth -26.2%, 3Y rev CAGR 8.7%
- -0.0% 10Y total return vs GRFS's -32.6%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TAK | 7.5% revenue growth vs GRFS's 0.2% |
| Value | TAK | Lower P/E (0.2x vs 9.6x) |
| Quality / Margins | GRFS | 5.3% margin vs TAK's 2.6% |
| Stability / Safety | TAK | Beta 0.33 vs GRFS's 1.12, lower leverage |
| Dividends | TAK | 3.6% yield, 2-year raise streak, vs GRFS's 2.5% |
| Momentum (1Y) | GRFS | +18.9% vs TAK's +14.3% |
| Efficiency (ROA) | GRFS | 2.0% ROA vs TAK's 0.7%, ROIC 5.4% vs 2.3% |
GRFS vs TAK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2024
GRFS vs TAK — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTAKLAGGINGGRFS
GRFSGrifols, S.A.
2leads
TAKTakeda Pharmaceutical…
3leads
6 Total Categories
CATEGORYLEADERvs GRFSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TAK4/6
Valuation MetricsMultiples, price ratios, and targets
GRFS5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GRFS8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
TAK2/2
Analyst OutlookRatings, price targets, and dividends
TAK1/1
Income & Cash Flow (Last 12 Months)
TAK leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TAK is the larger business by revenue, generating $4.49T annually — 597.7x GRFS's $7.5B. Profitability is closely matched — net margins range from 5.3% (GRFS) to 2.6% (TAK). On growth, TAK holds the edge at +6.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | GRFSGrifols, S.A. | TAKTakeda Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $7.5B | $4.49T |
| EBITDAEarnings before interest/tax | $1.6B | $1.14T |
| Net IncomeAfter-tax profit | $401M | $114.8B |
| Free Cash FlowCash after capex | $772M | $956.6B |
| Gross MarginGross profit ÷ Revenue | +38.4% | +62.1% |
| Operating MarginEBIT ÷ Revenue | +17.0% | +8.3% |
| Net MarginNet income ÷ Revenue | +5.3% | +2.6% |
| FCF MarginFCF ÷ Revenue | +10.3% | +21.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -0.6% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +40.0% | +3.4% |
TAK leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
GRFS leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 12.6x trailing earnings, GRFS trades at a 84% valuation discount to TAK's 77.7x P/E. On an enterprise value basis, GRFS's 8.6x EV/EBITDA is more attractive than TAK's 11.2x.
| Metric | GRFSGrifols, S.A. | TAKTakeda Pharmaceut… |
|---|---|---|
| Market CapShares × price | $7.1B | $52.8B |
| Enterprise ValueMkt cap + debt − cash | $16.4B | $79.3B |
| Trailing P/EPrice ÷ TTM EPS | 12.57x | 77.66x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.60x | 0.23x |
| PEG RatioP/E ÷ EPS growth rate | — | 4.10x |
| EV / EBITDAEnterprise value multiple | 8.63x | 11.21x |
| Price / SalesMarket cap ÷ Revenue | 0.84x | 1.80x |
| Price / BookPrice ÷ Book value/share | 0.64x | 1.21x |
| Price / FCFMarket cap ÷ FCF | 8.07x | 9.63x |
GRFS leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
GRFS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
GRFS delivers a 5.2% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $2 for TAK. TAK carries lower financial leverage with a 0.65x debt-to-equity ratio, signaling a more conservative balance sheet compared to GRFS's 1.15x. On the Piotroski fundamental quality scale (0–9), GRFS scores 6/9 vs TAK's 5/9, reflecting solid financial health.
| Metric | GRFSGrifols, S.A. | TAKTakeda Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | +5.2% | +1.5% |
| ROA (TTM)Return on assets | +2.0% | +0.7% |
| ROICReturn on invested capital | +5.4% | +2.3% |
| ROCEReturn on capital employed | +6.4% | +2.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 |
| Debt / EquityFinancial leverage | 1.15x | 0.65x |
| Net DebtTotal debt minus cash | $7.9B | $4.13T |
| Cash & Equiv.Liquid assets | $825M | $385.1B |
| Total DebtShort + long-term debt | $8.7B | $4.52T |
| Interest CoverageEBIT ÷ Interest expense | 2.05x | 1.97x |
GRFS leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — GRFS and TAK each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TAK five years ago would be worth $11,986 today (with dividends reinvested), compared to $4,978 for GRFS. Over the past 12 months, GRFS leads with a +18.9% total return vs TAK's +14.3%. The 3-year compound annual growth rate (CAGR) favors GRFS at 4.3% vs TAK's 2.9% — a key indicator of consistent wealth creation.
| Metric | GRFSGrifols, S.A. | TAKTakeda Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -9.0% | +9.0% |
| 1-Year ReturnPast 12 months | +18.9% | +14.3% |
| 3-Year ReturnCumulative with dividends | +13.6% | +8.9% |
| 5-Year ReturnCumulative with dividends | -50.2% | +19.9% |
| 10-Year ReturnCumulative with dividends | -32.6% | -0.0% |
| CAGR (3Y)Annualised 3-year return | +4.3% | +2.9% |
Evenly matched — GRFS and TAK each lead in 3 of 6 comparable metrics.
Risk & Volatility
TAK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TAK is the less volatile stock with a 0.33 beta — it tends to amplify market swings less than GRFS's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TAK currently trades 88.5% from its 52-week high vs GRFS's 75.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GRFSGrifols, S.A. | TAKTakeda Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 0.33x |
| 52-Week HighHighest price in past year | $11.14 | $18.89 |
| 52-Week LowLowest price in past year | $7.08 | $12.99 |
| % of 52W HighCurrent price vs 52-week peak | +75.5% | +88.5% |
| RSI (14)Momentum oscillator 0–100 | 50.9 | 34.9 |
| Avg Volume (50D)Average daily shares traded | 705K | 2.7M |
TAK leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
TAK leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates GRFS as "Buy" and TAK as "Buy". For income investors, TAK offers the higher dividend yield at 3.61% vs GRFS's 2.52%.
| Metric | GRFSGrifols, S.A. | TAKTakeda Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | 8 | 6 |
| Dividend YieldAnnual dividend ÷ price | +2.5% | +3.6% |
| Dividend StreakConsecutive years of raises | 2 | 2 |
| Dividend / ShareAnnual DPS | $0.18 | $94.22 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.0% | +0.6% |
TAK leads this category, winning 1 of 1 comparable metric.
Key Takeaway
TAK leads in 3 of 6 categories (Income & Cash Flow, Risk & Volatility). GRFS leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
Best OverallTakeda Pharmaceutical Compa… (TAK)Leads 3 of 6 categories
Loading custom metrics...
GRFS vs TAK: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is GRFS or TAK a better buy right now?
For growth investors, Takeda Pharmaceutical Company Limited (TAK) is the stronger pick with 7.
5% revenue growth year-over-year, versus 0. 2% for Grifols, S. A. (GRFS). Grifols, S. A. (GRFS) offers the better valuation at 12. 6x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate Grifols, S. A. (GRFS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GRFS or TAK?
On trailing P/E, Grifols, S.
A. (GRFS) is the cheapest at 12. 6x versus Takeda Pharmaceutical Company Limited at 77. 7x. On forward P/E, Takeda Pharmaceutical Company Limited is actually cheaper at 0. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — GRFS or TAK?
Over the past 5 years, Takeda Pharmaceutical Company Limited (TAK) delivered a total return of +19.
9%, compared to -50. 2% for Grifols, S. A. (GRFS). Over 10 years, the gap is even starker: TAK returned -0. 0% versus GRFS's -32. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GRFS or TAK?
By beta (market sensitivity over 5 years), Takeda Pharmaceutical Company Limited (TAK) is the lower-risk stock at 0.
33β versus Grifols, S. A. 's 1. 12β — meaning GRFS is approximately 245% more volatile than TAK relative to the S&P 500. On balance sheet safety, Takeda Pharmaceutical Company Limited (TAK) carries a lower debt/equity ratio of 65% versus 115% for Grifols, S. A. — giving it more financial flexibility in a downturn.
05Which is growing faster — GRFS or TAK?
By revenue growth (latest reported year), Takeda Pharmaceutical Company Limited (TAK) is pulling ahead at 7.
5% versus 0. 2% for Grifols, S. A. (GRFS). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -26. 2% for Takeda Pharmaceutical Company Limited. Over a 3-year CAGR, TAK leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GRFS or TAK?
Grifols, S.
A. (GRFS) is the more profitable company, earning 5. 3% net margin versus 2. 4% for Takeda Pharmaceutical Company Limited — meaning it keeps 5. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRFS leads at 16. 4% versus 7. 5% for TAK. At the gross margin level — before operating expenses — TAK leads at 65. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GRFS or TAK more undervalued right now?
On forward earnings alone, Takeda Pharmaceutical Company Limited (TAK) trades at 0.
2x forward P/E versus 9. 6x for Grifols, S. A. — 9. 4x cheaper on a one-year earnings basis.
08Which pays a better dividend — GRFS or TAK?
All stocks in this comparison pay dividends.
Takeda Pharmaceutical Company Limited (TAK) offers the highest yield at 3. 6%, versus 2. 5% for Grifols, S. A. (GRFS).
09Is GRFS or TAK better for a retirement portfolio?
For long-horizon retirement investors, Takeda Pharmaceutical Company Limited (TAK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
33), 3. 6% yield). Both have compounded well over 10 years (TAK: -0. 0%, GRFS: -32. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GRFS and TAK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: GRFS is a small-cap deep-value stock; TAK is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(GRFS: -0.6% · TAK: 6.0%)Net Margin>
%
(GRFS: 5.3% · TAK: 2.6%)P/E Ratio<
x
(GRFS: 12.6x · TAK: 77.7x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.